The serine palmitoyl transferase inhibitor myriocin potently suppresses the development of
atherosclerosis in apolipoprotein E (apoE) gene knockout (apoE−/−) mice fed a high-fat diet.
This is associated with reduced plasma sphingomyelin (SM) and glycosphingolipid levels.
Furthermore, oral administration of myriocin decreases plasma cholesterol and triglyceride
(TG) levels. Here, we aimed to determine whether myriocin could inhibit the progression (or
stimulate the regression) of established atherosclerotic lesions and to examine potential …